Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
- First NSW Health supply expected in the December 2026 quarter
- Five product registrations under review by the TGA
- AOS2 identified about 2.5 times the proportion of confirmed synergies versus AOS1
- 40 multi-anchor combinations to undergo a third Peter Mac validation program
- $6.15 million in reported cash and available funding at quarter end
NSW Health contract moves towards first supply
Algorae Pharmaceuticals Ltd (ASX:1AI) is approaching its first tangible commercial test after AlgoraeRx was appointed one of several suppliers under a NSW Health public hospital arrangement. The initial term runs for three years, with two optional one-year extensions, and first supply under purchase orders is expected in the December 2026 quarter.
The appointment gives Algorae access to one of Australia’s largest healthcare procurement networks, but it is not a guaranteed revenue stream. The arrangement is non-exclusive, carries no minimum volume or spending commitments, and product identity, pricing and volumes remain confidential. Algorae said it does not expect the award, by itself, to have a material impact on revenue in the current calendar year. The company had previously flagged the NSW Health supply contract, with the latest report narrowing the focus to purchase orders and actual supply.
TGA pipeline expands beyond the initial contract
AlgoraeRx is building a broader pharmaceutical platform alongside the NSW Health opportunity. Its Licence & Supply network now covers more than 20 products and five manufacturing partners across oncology, cardiovascular, metabolic and specialty medicines, while five product registrations are under review by the Therapeutic Goods Administration.
Post-quarter developments added another strand to that pipeline. AlgoraeRx signed a binding licence and supply agreement with Umedica Laboratories for one product, whose dossier has been submitted to the TGA, while a separate memorandum of understanding covers exclusive Australian importing, distribution and commercial partnership rights across eight Umedica-branded molecules. The latter arrangement remains non-binding, with definitive agreements still to be negotiated; the company’s Umedica TGA dossier had been reported as awaiting approval.
AOS2 produces stronger preclinical synergy signal
Algorae’s second independent validation program at the Victorian Centre for Functional Genomics and Peter MacCallum Cancer Centre produced the quarter’s main research signal. Across 24 drugs selected by AOS2 for predicted synergy with CBD, four cancer cell lines and roughly 10,000 data points, AOS2 identified approximately a 2.5-fold higher proportion of confirmed synergistic combinations than the preliminary AOS1 model, using the company’s internal thresholds.
That result is preclinical rather than clinical evidence, and it does not establish regulatory approval or commercial success. It does, however, provide the basis for further assessment of several combinations and possible intellectual property review. The result builds on the AOS2 independent validation reported in July, when the company described improved prediction performance across CBD-related combinations.
Forty multi-anchor combinations enter testing
Algorae has since agreed a third Peter Mac program to screen 40 high-priority drug combinations drawn from its multi-anchor model. The candidates were selected from a much larger in-silico exercise involving more than nine million drug-drug-cell-line combinations and more than 6,000 multi-cell-line combinations. Testing will cover four cancer cell lines representing glioblastoma, non-small cell lung cancer, colorectal cancer and bladder cancer, with the full dataset expected within six months.
A $49,109 Phenomics Australia Pipeline Accelerator grant will co-fund the work. Algorae said priority candidates from its first two Peter Mac programs have also been shortlisted for possible further in-vitro and animal-model assessment, although those next steps remain subject to ongoing discussions and validation.
Cash position leaves room for execution
Cash and cash equivalents fell to $3.15 million at 30 September from $3.94 million three months earlier, after $787,456 of net operating cash use. Product manufacturing and operating costs accounted for $249,460, while research and development consumed $133,246; the company also reported $28,815 in customer receipts during the quarter.
Algorae had not drawn its $3 million revolving ScotPac working-capital facility, leaving reported total available funding of $6.15 million. On the quarter’s operating cash-use rate, the Appendix 4C calculates 7.8 quarters of funding. That measure is a snapshot, not a forecast: manufacturing needs, regulatory work, supply volumes and research spending could all alter the pace of cash use as the company moves from pipeline-building towards commercial supply.
Bottom Line?
The next proof point is operational rather than promotional: whether NSW Health purchase orders arrive, while TGA decisions and the 40-combination validation program test the depth of Algorae’s pipeline.
Questions in the middle?
- What volume of NSW Health purchase orders will Algorae receive once supply begins, given the absence of minimum commitments?
- Will any of the five products under TGA review clear registration in time to support near-term commercial revenue?
- Do the 40 multi-anchor candidates reproduce the AOS2 signal strongly enough to justify further preclinical or intellectual property investment?